Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620879 | 0.88 | GPR119 (0.47) | GPR119KMT2ANAMPTCHRM2CHRM1 | |
| SCHEMBL7390760 | 0.84 | LIPE (0.55) | GPR119KMT2APOLBMMP13 | |
| SCHEMBL7396050 | 0.83 | KMT2A (0.50) | GPR119KMT2A | |
| SCHEMBL2556948 | 0.81 | GPR119 (0.69) | GPR119CHRM2CHRM1 | |
| SCHEMBL2556476 | 0.81 | GPR119 (0.69) | GPR119CHRM2CHRM1 | |
| SCHEMBL3399260 | 0.79 | GPR119 (0.47) | GPR119KMT2AHRH3 | |
| SCHEMBL3914633 | 0.79 | MLNR (0.49) | GPR119KMT2AHRH3 | |
| SCHEMBL24596887 | 0.78 | CYP4F2 (0.51) | GPR119KMT2ANAMPTHRH3 | |
| SCHEMBL2116540 | 0.78 | GPR119 (0.65) | GPR119HRH3 | |
| SCHEMBL5273710 | 0.78 | SMN1; SMN2 (0.50) | GPR119KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007735-A1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | Glaxo Group Limited (GB) | 2008-12-31 | — | — | EP | disclosed |
| EP-1906964-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007122156-A9 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007122156-A1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007009741-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| EP-1610786-A1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LIMITED (GB) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089373-A1 | 4- (4-(HETEROCYCLYLALKOXY}PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER’S | GLAXO GROUP LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |